DWTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Dogwood Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$1.21−0.01 (-0.82%)
Close on Oct 19, 2026
- Market cap
- $41.30M
- P/E (TTM)
- –
- Dividend yield
- –
Dogwood Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Dogwood Therapeutics | Industry median |
|---|---|---|
| Market Cap | $41.13M | $166.30M |
| Enterprise Value | $31.52M | $88.19M |
| PB Ratio | 0.60 | 2.03 |
Income (trailing twelve months)
| Measure | Dogwood Therapeutics | Industry median |
|---|---|---|
| Operating Income | -$38.76M | -$21.40M |
| Pretax Income | -$38.49M | -$14.34M |
| Net Income | -$36.04M | -$22.46M |
| EBITDA | -$38.76M | -$16.91M |
Returns
| Measure | Dogwood Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -95.8% | -53.2% |
| Return on Assets (ROA) | -40.7% | -40.9% |
| Return on Invested Capital (ROIC) | -117.2% | -32.4% |
| Return on Capital Employed (ROCE) | -49.9% | -38.1% |
Balance sheet
| Measure | Dogwood Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $9.61M | $61.43M |
| Net Cash (Debt) | $9.61M | $15.35M |
| Net Cash Per Share | $0.28 | $0.66 |
| Equity (Book Value) | $68.37M | $49.09M |
| Book Value Per Share | $2.01 | $1.37 |
| Tangible Book Value | -$942.54K | $23.52M |
| Working Capital | $8.19M | $76.81M |
Financial position
| Measure | Dogwood Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 3.89 | 3.34 |
| Quick Ratio | 3.39 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Dogwood Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$15.11M | -$12.35M |
Efficiency
| Measure | Dogwood Therapeutics | Industry median |
|---|---|---|
| Profits Per Employee | -$4.51M | -$703.34K |
| Employee Count | 8 | 74 |
Dividends and yields
| Measure | Dogwood Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -87.6% | -23.3% |
Shares
| Measure | Dogwood Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 33,992,600 | 58,127,000 |
| Shares Change (QoQ) | 0.68% | 0.54% |
| Shares Held by Institutions | 11.3% | 59.4% |
Scores
| Measure | Dogwood Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -1.60 | -0.22 |
| Piotroski F-Score | 2 | 4 |
Calculated by StockData from Dogwood Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.